Articles tagged with Breast Cancer
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A study of post-menopausal women found that hormone therapy increased the risk of abnormal mammograms and breast biopsies, while also decreasing the effectiveness of these methods for detecting breast cancer. The therapy may delay diagnosis and increase breast density, which can lead to a higher risk of breast cancer.
A recent study published in Archives of Internal Medicine found that combined hormone therapy significantly increases the risk of abnormal mammograms and breast biopsies, compromising their diagnostic performance. The research involved 16,608 post-menopausal women and revealed a four percent greater risk of mammogram abnormalities afte...
Researchers at NIST, NCI, and SAIC developed a new method for detecting HER2 breast cancer using chicken immunoglobulin Y (IgY) antibody tagged with quantum dot. This approach improves the detection of HER2 biomarker by 40-50% compared to existing tests.
Researchers at the MUHC have identified HSP90 as a promising therapeutic target for ocular melanoma. By targeting this protein, it is possible to disrupt multiple cellular functions and block cancer cell reproduction, leading to tumour regression.
A growing body of evidence supports preventive measures for high-risk women, including those with BRCA1 and BRCA2 mutations. Primary care physicians should learn about genetics, take a comprehensive personal and family history to advise patients at increased risk.
Research found that DDT's main metabolite, p,p'-DDE, disrupts hormone-sensitive breast cancer cells by opposing the androgen signalling pathway. This suggests a new mechanism for breast cancer progression, potentially favouring tumour growth in women.
Researchers at Yale School of Medicine have developed a blood test that detects early stage ovarian cancer with 99% accuracy, building on previous work showing 95% effectiveness. The new platform uses six protein biomarkers instead of four, increasing specificity from 95 to 99.4%.
A study found that women with ductal carcinoma in situ (DCIS) have overly optimistic views of their risk of recurrence and invasive breast cancer. Anxiety levels decreased over time, but depression remained low. Clinicians should be aware of these inaccurate perceptions to minimize distress.
A study led by Dana-Farber Cancer Institute researchers found that women with ductal carcinoma in situ (DCIS) often misperceive their risk of recurrence or dying from breast cancer, due to elevated anxiety. This can lead to poor treatment choices and negatively impact emotional well-being and health behaviors.
A study found that breast cancer survivors, especially older women, are at a greater risk of dying from non-cancer causes than from breast cancer. Factors such as pre-existing diseases like heart disease and osteoporosis are associated with this increased risk. The researchers also found that women with cancer cells in the lymph nodes ...
Researchers found 41 inaccurate statements on 18 websites, 5.2% of total analyzed web pages. Despite quality criteria, no combination could differentiate accurate from inaccurate content.
A new study found that 41 false statements appeared on 18 web pages (5.2%) and that websites with complementary or alternative medicine were 15.6 times more likely to have inaccuracies. The authors advise patients to be skeptical of online health information and consult a clinician before taking action.
A new study by Memorial Sloan Kettering Cancer Center found that risk-reducing salpingo-oophorectomy (RRSO) is associated with a 72% breast cancer risk reduction in women with BRCA2 mutations, compared to 38% for BRCA1 mutation carriers. The surgery also reduced the risk of gynecologic cancer by 85% in women with a BRCA1 mutation.
Researchers identified CDK10 as a key factor in breast cancer treatment resistance, which occurs earlier in tumors expressing low levels of the protein. The study also found that methylation of the CDK10 gene correlates with resistance.
A study by Dr. Catherine Sabiston found that breast cancer survivors who participated in dragon boat racing reported significantly improved physical and mental health. The social aspect of the activity provided a sense of community and empowerment, helping women cope with post-recovery trauma.
Research found women living in gentrifying neighborhoods in Cook County are at higher risk of distant-stage metastasis than those in similar non-gentrified areas. Disruption to social networks and access to healthcare services may contribute to the increased risk.
Researchers found that BRCA1 plays a role in regulating breast stem cells, which can develop into cancers. Women with BRCA1 mutations have a high incidence of breast cancer due to the unregulated proliferation of these stem cells.
Researchers analyzed data from nearly 30,000 women with breast cancer and found that female surgeons were more likely to prescribe post-surgical radiation therapy. Women who received radiation had a surgeon trained in the US or with an M.D. degree compared to a D.O. degree.
Researchers found Ki-67 expression associated with poorer disease-free survival, but not predictive of chemotherapy benefit. Pathology reports offer a reliable alternative for determining ER status in breast cancer trials.
A national study found digital mammography performed better than film in pre- and perimenopausal women under 50 with dense breasts. The study, DMIST, also showed improved diagnostic accuracy for digital mammography over film for some subgroups.
Two microRNAs, miR-373 and miR-520c, have been identified as promoting the spread of tumor cells. The study found that miR-373 is a potential biomarker for metastatic breast cancer and may be used to develop new treatments.
The PEM/PET system can spot tumors half the size of standard imaging systems, and complete an image and biopsy in a similar time frame. It features high-resolution PET images of the breast, guiding needle biopsies with a robot arm.
A study of 227 breast cancer patients found that those who participated in a psychological intervention program had better health and functioning scores, with a 7% increase compared to non-participants. The program included training on relaxation, coping with stress, and strategies for improving health behaviors, resulting in fewer sym...
A study by Brown University and Harvard Medical School found that health insurance co-payments significantly reduce mammography use among women. The researchers analyzed data from Medicare managed-care plans and found a 8-11% decrease in breast cancer screening rates among women with co-payments, compared to those with full coverage.
A study found surgical site infections in 5.3% of patients following breast surgery, with higher costs and longer hospital stays for infected patients. The cost of surgical site infections was estimated at $4,091 per patient.
Researchers at Duke University Medical Center have identified a new pathway involving BRCA1 in repairing damaged DNA, which may explain the increased breast cancer risk in women with mutated BRCA1 genes. This discovery could lead to more effective therapies for women with and without BRCA1 mutations.
Researchers have identified cyclin D1 as a key player in ER+ breast cancers, which are the most common type of breast cancer. The study found that inhibiting cyclin D1 function may provide a new treatment strategy for these tumors.
Postmenopausal women taking combined estrogen/progestin hormone-replacement therapy for three years or more face a significant increased risk of developing various forms of lobular breast cancer. The study, which confirms previous reports, suggests that even short exposure to such hormones may confer an increased risk.
Researchers have identified specific protein markers in human saliva that can provide an early, non-invasive diagnosis of breast cancer. The study found 49 proteins that differentiated healthy patients from those with benign and malignant breast tumors.
The Joni Gladowsky Breast Cancer Foundation has funded CSHL's innovative breast cancer research, led by Dr. Senthil Muthuswamy, to develop alternative treatment strategies for early-stage breast cancer. The foundation aims to identify genetic differences between benign and malignant lesions to prevent cancer progression.
Researchers identified three microRNA molecules that suppress the spread of breast cancer. Restoring these molecules reduces the ability of cancer cells to proliferate and migrate. The study adds to the growing list of cellular targets for drugs designed to prevent breast cancer metastasis.
A study by Memorial Sloan-Kettering Cancer Center identifies a group of microRNA molecules that control genes causing breast cancer metastasis. The loss of these microRNAs allows cancer cells to migrate and grow more rapidly, leading to increased risk of lung and bone metastasis.
A randomized clinical trial found that adding docetaxel to anthracycline-based chemotherapy improved disease-free survival in breast cancer patients. The study showed a 4% increase in five-year disease-free survival rates, with patients receiving sequential docetaxel after doxorubicin having the best outcomes.
The study found significant variation in breast cancer risk among BRCA1 and BRCA2 carriers, with younger age at diagnosis associated with increased risk for relatives. The research highlights the need for accurate estimation of risks and tailored interventions.
A new study analyzing over 2,000 women found that BRCA1 and BRCA2 carrier status varies significantly in relation to breast cancer incidence. The research highlights the importance of considering additional genetic factors beyond known mutations when assessing risk.
A new study found that racial disparities in cancer care have persisted despite efforts to mitigate them. Black patients are significantly less likely than white patients to receive therapy for certain types of cancer, including lung, breast, colon, and prostate cancer.
A recent study by Yale researchers found significant racial disparities in cancer therapy, with black patients less likely than white counterparts to receive treatment for various cancers. Despite efforts to improve access to care, the disparities persisted, highlighting the need for continued work to address these issues.
Research from the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) found that chemotherapy safely reduced recurrence, breast cancer mortality, and death from any cause in women with hormone-resistant breast cancer. The study showed a 10-year risk reduction of 25% in younger women and 39% in women aged 50-69 years.
Research published in the Journal of Clinical Oncology found that Ashkenazi Jewish women with BRCA1 or BRCA2 gene mutations have a significantly longer survival rate compared to those without these mutations. After up to nine years of follow-up, carriers were 28% less likely to die from ovarian cancer.
A study found that targeted digital mammography screening can be cost-effective for younger women with dense breasts, while conventional film mammography may be more effective for older women. Additionally, labeling epinephrine as a dose or ratio affected dosing errors among doctors.
Researchers at the Salk Institute found that early-stage breast cancer cells with high motility pose an increased risk of metastasis. These cells can wander along milk ducts and seed new tumors within the same breast, suggesting a need for earlier intervention.
Researchers discovered that cone-beam breast CT provides exceptional tissue contrast and can reduce examination time with comparable radiation dose to conventional 2D mammography. The study found well-resolved images of skin, adipose, and glandular regions, as well as clear detection of microcalcifications within cancers.
The study showed significant benefits of Avastin with Taxol in treating metastatic breast cancer, nearly doubling the time between chemotherapy initiation and tumor progression. This achievement demonstrates Avastin's potential as an antiangiogenic agent in breast cancer therapy.
A large clinical trial found that bevacizumab significantly prolongs progression-free survival for women with recurrent breast cancer when combined with chemotherapy. The study showed a doubling of delay in worsening of the disease and improved remission rates compared to chemotherapy alone.
Breast cancer patients who received tamoxifen or chemotherapy had a reduced risk of developing a second cancer in the other breast. Chemotherapy was associated with a 43% risk reduction, lasting up to 10 years, while tamoxifen use resulted in a 34% risk reduction that persisted for five years.
A genetic mutation known to affect Ashkenazi Jewish breast cancer patients is also prevalent among Hispanic and young African-American women. Research found that 3.5% of Hispanic women had the BRCA1 mutation, while 16.7% of African-American women under 35 did so.
The study found that anthracycline-based chemotherapy improves disease-free and overall survival rates more than non-anthracycline-based regimens for women with HER2-positive tumors. However, the treatment showed no significant benefit for patients with HER2-negative breast cancer.
Most general surgeons fail to discuss breast reconstruction with breast cancer patients before surgery. Researchers found only 33% of eligible patients had this conversation. Younger, more educated patients were more likely to have the discussion, leading to greater willingness to consider mastectomy.
A study published in Journal of Clinical Oncology found that nearly 50% of women over 65 with early stage hormone-positive breast cancer discontinue Tamoxifen treatment before five years. Factors predicting premature discontinuation include age, medical illnesses, and lack of radiation after surgery.
A new study estimated the costs of providing comprehensive screening and diagnostic services to under- or uninsured, low-income women. The median cost of screening a woman for breast cancer was $94, while the cost per detected case was $10,566. For cervical cancer, these costs were $56 and $13,340, respectively.
A new study from the University of Michigan Comprehensive Cancer Center found that only a third of breast cancer patients discussed reconstruction options with their surgeon. Women who did discuss reconstruction were four times more likely to choose a mastectomy, highlighting the importance of informed decision-making in surgical choices.
A microchip-based device, called the CTC-chip, can isolate, enumerate, and analyze circulating tumor cells from blood samples. The device was tested on 68 patients with five different types of tumors and showed a sensitivity rating of 99%, accurately monitoring response to treatment.
Researchers at CSHL have identified and repressed breast cancer stem cells in mouse tissue by manipulating microRNAs, suggesting a potential therapeutic target for breast cancer treatment. The study found that the delivery of the microRNA let-7 to breast-tissue cells can help distinguish stem-like tumor-initiating cells from other cells.
Researchers at the University of Pennsylvania have identified that dioxin targets the mitochondria, disrupting normal cellular function and promoting tumor progression. The study's findings suggest that understanding this mechanism could lead to new ways to block the propagation of mitochondrial stress signaling and inhibit cancer growth.
A combination of lapatinib and capecitabine significantly shrinks brain metastases in patients with aggressive HER2-positive breast cancer, with 10 patients experiencing a 50% reduction. The study's findings offer new hope for treatment options for women with advanced breast cancer who develop brain metastases.
A survey of 367 women with advanced breast cancer underscores the significance of emotional and educational needs, with psychosocial support identified as a high priority. The study also reveals dissatisfaction with treatment experiences and highlights the importance of internet access as an information resource for patients.
Two studies from Mayo Clinic found that ER/PR negative breast cancers have the worst overall outcomes when spreading to the brain, resulting in shorter median survival times. Women with triple negative tumors and HER2+ tumors without estrogen or progesterone receptors have poor outcomes due to aggressive brain metastasis.
A Mayo Clinic program has reduced delays between abnormal mammograms and diagnosis, improving outcomes for women with cancer. The clinic's multidisciplinary breast clinic helped overcome barriers such as lack of transportation and childcare, providing timely care to underserved women.
Researchers found that grade 2 and 3 tumors are more common in HER2+ and triple negative cancers, which have a higher risk of growth and relapse. Cancer came back frequently in these subtypes, with a death rate higher in triple negative breast cancer.
A new study published by Mayo Clinic researchers found that Herceptin helps women with HER2+ type of breast cancer independent of whether they have extra copies of chromosome 17. The analysis showed significant benefits for patients with polysomy 17, including a disease-free survival rate of 89% after three years of treatment.